Stock Analiz

Rhythm Pharmaceuticals, Inc. (RYTM) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$197M, a net margin of -103.6%; the best year in this period was 2016 with -$29M.

Over the twelve months to September 30, 2026, revenue was $281M and net income -$198M.

Free cash flow was -$117M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 537% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $0162017: $0172018: $0182019: $0192020: $0202021: $3M212022: $24M222023: $77M232024: $130M242025: $190M25$190M
Net income
2016: -$29M162017: -$34M172018: -$74M182019: -$141M192020: -$134M202021: -$70M212022: -$181M222023: -$185M232024: -$261M242025: -$197M25-$197M
Free cash flow
2016: -$24M162017: -$30M172018: -$63M182019: -$126M192020: -$122M202021: -$146M212022: -$174M222023: -$136M232024: -$114M242025: -$117M25-$117M
EPS (diluted)
2016: $-2.85162017: $-2.83172018: $-2.39182019: $-3.86192020: $-3.04202021: $-1.40212022: $-3.47222023: $-3.20232024: $-4.34242025: $-3.1125$-3.11

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$281M$190M$130M$77M$24M$3M$0$0$0$0$0
Gross profit$248M$170M$117M$68M$22M$3M—————
Operating income-$187M-$192M-$266M-$184M-$179M-$170M-$137M-$146M-$78M-$32M-$26M
Net income-$198M-$197M-$261M-$185M-$181M-$70M-$134M-$141M-$74M-$34M-$29M
EPS (diluted)$-2.90$-3.11$-4.34$-3.20$-3.47$-1.40$-3.04$-3.86$-2.39$-2.83$-2.85
R&D$180M$167M$238M$135M$109M$104M$90M$109M$50M$23M$20M
Revenue growth—+45.8%+68.1%+227.6%+649.5%——————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$82M-$116M-$114M-$136M-$173M-$146M-$122M-$123M-$62M-$29M-$23M
Capital spending-$1M-$953000$0-$47000-$281000-$434000-$214000-$3M-$722000-$133000-$1M
Free cash flow-$83M-$117M-$114M-$136M-$174M-$146M-$122M-$126M-$63M-$30M-$24M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$93M$67M$40M$33M$20M$21M$17M$12M$6M$2M$1M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$389M$321M$276M$333M$295M$173M$292M$50M$34M$7M
Debt—$112M$114M$107M$2M$3M$3M$4M$4M——
Equity—$139M$22M$170M$264M$284M$167M$281M$246M$145M-$33M
Total assets—$480M$392M$333M$382M$330M$187M$309M$260M$152M$12M
Shares (diluted)69M65M61M58M52M50M44M36M31M13M10M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin88.2%89.7%89.7%88.0%91.0%81.0%—————
Operating margin-66.7%-101.2%-204.0%-238.1%-757.9%-5391.9%—————
Net margin-70.6%-103.6%-200.3%-238.5%-766.2%-2207.1%—————
FCF margin-29.6%-61.5%-87.5%-175.9%-734.9%-4642.9%—————
ROIC—-60.4%-154.8%-52.5%-53.2%-46.9%-63.6%-40.5%-24.8%-17.7%—
ROE—-141.3%-1199.3%-108.8%-68.5%-24.5%-80.5%-50.1%-30.1%-23.3%88.9%

Frequently asked questions

What is Rhythm Pharmaceuticals’s annual revenue?

$190M in fiscal 2025 and $281M over the twelve months to September 30, 2026.

How much profit does Rhythm Pharmaceuticals make?

Net income was -$197M in fiscal 2025 (net margin -103.6%).

Is Rhythm Pharmaceuticals’s revenue growing?

Yes: revenue rose 45.8% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.